Aurora Cannabis closes Bevo Agtech deal to strengthen supply chain and R&D
- Aurora completed buying Bevo Agtech to boost agtech capabilities, supply‑chain resilience and accelerate global product innovation. • Management says Bevo will improve yield predictability, reduce input variability and shorten time‑to‑market for new formulations. • Aurora positions the integration to expand high‑margin medical offerings, leveraging GMP facilities across Canada and Germany.
Aurora closes agtech deal to strengthen supply chain and R&D
Aurora Cannabis is completing a transaction with Bevo Agtech that the company says bolsters its agricultural-technology capabilities and strengthens supply‑chain resilience across its global footprint. The deal, first disclosed on Feb. 4 and confirmed complete on Feb. 17, is intended to accelerate product innovation and scale in Aurora’s medical and consumer markets by integrating Bevo’s agtech expertise into Aurora’s existing cultivation and processing operations.
Company management frames the transaction as a strategic step to support near‑term commercial and operational milestones, saying the added capabilities will enhance yield predictability, reduce input variability and shorten time to market for new formulations. Aurora directs investors and stakeholders to the Feb. 4 press release and mandatory filings on SEDAR+ for full details of the terms, rationale and the management outlook that accompanies the transaction.
Aurora is positioning the Bevo integration as complementary to its medical‑first strategy and existing manufacturing footprint, which includes GMP‑certified facilities in Canada and Germany. The company emphasizes that improved agtech and supply‑chain robustness will underpin efforts to expand high‑margin medical offerings and support long‑term patient care objectives.
CFO to present strategy at TD Cowen health care conference
Aurora’s chief financial officer, Simona King, is taking part in a fireside chat and one‑on‑one investor meetings at TD Cowen’s 46th Annual Health Care Conference in Boston on March 2. The live audio webcast, hosted by TD Cowen’s Derek Lessard, is accessible through Aurora’s investor events page, with a replay available for about 90 days.
Conference remarks are slated to cover Aurora’s international leadership, shifts reshaping the global medical cannabis landscape, advancements in Canadian manufacturing excellence and market forces influencing industry growth. The presentation gives management a forum to outline how the Bevo Transaction feeds into commercial plans and operational guidance.
Operations, brands and market footprint
Aurora serves medical and consumer markets across Canada, Europe, Australia and New Zealand and markets brands including Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty’s and Whistler Medical Marijuana Co. The company emphasizes scientific expertise, proven performance and patient care while integrating new agtech capabilities to support scalability and product development.